Evidence-based management of dermatophytosis in India today
Introduction: Dermatophyte infection has become extremely resistant and widespread in all parts of India during the past decade. A change in the major causative organism has been identified to be a major factor behind the change in the character of the infection. The epidemiological shift has been a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2023;volume=20;issue=1;spage=32;epage=37;aulast=Ghosh |
| _version_ | 1797866754763915264 |
|---|---|
| author | Aparajita Ghosh Saumya Panda |
| author_facet | Aparajita Ghosh Saumya Panda |
| author_sort | Aparajita Ghosh |
| collection | DOAJ |
| description | Introduction: Dermatophyte infection has become extremely resistant and widespread in all parts of India during the past decade. A change in the major causative organism has been identified to be a major factor behind the change in the character of the infection. The epidemiological shift has been accompanied by large scale antifungal resistance. This review aims to take a look at the current status of evidence regarding the effectiveness of major antifungal molecules, with particular reference to the current epidemic-like scenario of resistant dermatophytosis in India. Methods: We have searched and included the relevant literature on “Dermatophytosis” from the PubMed, Scopus, and Google Scholar. Results: The current situation has also brought into focus the glaring lack of evidence-based guidelines for the management of dermatophytosis. The guidelines available previously had mostly been based on the western literature with the scarcity of studies from tropical countries such as India. Conclusion: The current guidelines of the management of dermatophytosis have lost their relevance in the present scenario and need to be replaced. However, without adequate studies we do not have robust data to formulate the new guidelines. |
| first_indexed | 2024-04-09T23:29:21Z |
| format | Article |
| id | doaj.art-1b709838357e48799f31258b82ccba8d |
| institution | Directory Open Access Journal |
| issn | 0976-0016 2213-3682 |
| language | English |
| last_indexed | 2024-04-09T23:29:21Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj.art-1b709838357e48799f31258b82ccba8d2023-03-21T07:25:18ZengWolters Kluwer Medknow PublicationsApollo Medicine0976-00162213-36822023-01-01201323710.4103/am.am_171_22Evidence-based management of dermatophytosis in India todayAparajita GhoshSaumya PandaIntroduction: Dermatophyte infection has become extremely resistant and widespread in all parts of India during the past decade. A change in the major causative organism has been identified to be a major factor behind the change in the character of the infection. The epidemiological shift has been accompanied by large scale antifungal resistance. This review aims to take a look at the current status of evidence regarding the effectiveness of major antifungal molecules, with particular reference to the current epidemic-like scenario of resistant dermatophytosis in India. Methods: We have searched and included the relevant literature on “Dermatophytosis” from the PubMed, Scopus, and Google Scholar. Results: The current situation has also brought into focus the glaring lack of evidence-based guidelines for the management of dermatophytosis. The guidelines available previously had mostly been based on the western literature with the scarcity of studies from tropical countries such as India. Conclusion: The current guidelines of the management of dermatophytosis have lost their relevance in the present scenario and need to be replaced. However, without adequate studies we do not have robust data to formulate the new guidelines.http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2023;volume=20;issue=1;spage=32;epage=37;aulast=Ghoshantifungal susceptibility testevidence-based managementitraconazoleluliconazolemiconazoleterbinafinetrichophyton indotinaeupper limit of wild typevoriconazole |
| spellingShingle | Aparajita Ghosh Saumya Panda Evidence-based management of dermatophytosis in India today Apollo Medicine antifungal susceptibility test evidence-based management itraconazole luliconazole miconazole terbinafine trichophyton indotinae upper limit of wild type voriconazole |
| title | Evidence-based management of dermatophytosis in India today |
| title_full | Evidence-based management of dermatophytosis in India today |
| title_fullStr | Evidence-based management of dermatophytosis in India today |
| title_full_unstemmed | Evidence-based management of dermatophytosis in India today |
| title_short | Evidence-based management of dermatophytosis in India today |
| title_sort | evidence based management of dermatophytosis in india today |
| topic | antifungal susceptibility test evidence-based management itraconazole luliconazole miconazole terbinafine trichophyton indotinae upper limit of wild type voriconazole |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2023;volume=20;issue=1;spage=32;epage=37;aulast=Ghosh |
| work_keys_str_mv | AT aparajitaghosh evidencebasedmanagementofdermatophytosisinindiatoday AT saumyapanda evidencebasedmanagementofdermatophytosisinindiatoday |